drugset / Trial / NCT00576225
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
Timeline
- Start
- 2007-09
- Primary completion
- 2010-04-05
- Completion
- 2010-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | paclitaxel poliglumex | Other / unclassified | 175 mg/m2 | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |